CEACAM5 and colorectal cancer: Some clinical trials are ongoing using the trivalent bispecific anti-CEA and anti-HSG antibody TF2 and the 177Lu-DOTA-di-HSG-peptide IMP-288 in patients with colorectal cancer and small cell lung cancer.